These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 37503262)

  • 1. Total network controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    Res Sq; 2023 Jul; ():. PubMed ID: 37503262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Total network controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    Biol Direct; 2023 Sep; 18(1):55. PubMed ID: 37670359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total controllability analysis discovers explainable drugs for Covid-19 treatment.
    Wei X; Pan C; Zhang X; Zhang W
    ArXiv; 2023 Jun; ():. PubMed ID: 35677421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of oral therapeutics using an AI platform against the virus responsible for COVID-19, SARS-CoV-2.
    Bess A; Berglind F; Mukhopadhyay S; Brylinski M; Alvin C; Fattah F; Wasan KM
    Front Pharmacol; 2023; 14():1297924. PubMed ID: 38186640
    [No Abstract]   [Full Text] [Related]  

  • 5. Signaling network analysis reveals fostamatinib as a potential drug to control platelet hyperactivation during SARS-CoV-2 infection.
    Osmanoglu Ö; Gupta SK; Almasi A; Yagci S; Srivastava M; Araujo GHM; Nagy Z; Balkenhol J; Dandekar T
    Front Immunol; 2023; 14():1285345. PubMed ID: 38187394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generic model to unravel the deeper insights of viral infections: an empirical application of evolutionary graph coloring in computational network biology.
    Kole A; Bag AK; Pal AJ; De D
    BMC Bioinformatics; 2024 Feb; 25(1):74. PubMed ID: 38365632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current Strategies of Antiviral Drug Discovery for COVID-19.
    Mei M; Tan X
    Front Mol Biosci; 2021; 8():671263. PubMed ID: 34055887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug repurposing for COVID-19 using computational screening: Is Fostamatinib/R406 a potential candidate?
    Saha S; Halder AK; Bandyopadhyay SS; Chatterjee P; Nasipuri M; Bose D; Basu S
    Methods; 2022 Jul; 203():564-574. PubMed ID: 34455072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting hub genes and pathways of innate immune response in COVID-19: A network biology perspective.
    Prasad K; Khatoon F; Rashid S; Ali N; AlAsmari AF; Ahmed MZ; Alqahtani AS; Alqahtani MS; Kumar V
    Int J Biol Macromol; 2020 Nov; 163():1-8. PubMed ID: 32599245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study].
    Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R
    Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.
    Sohag AAM; Hannan MA; Rahman S; Hossain M; Hasan M; Khan MK; Khatun A; Dash R; Uddin MJ
    Drug Dev Res; 2020 Dec; 81(8):919-941. PubMed ID: 32632960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Coronavirus Network Explorer: mining a large-scale knowledge graph for effects of SARS-CoV-2 on host cell function.
    Krämer A; Billaud JN; Tugendreich S; Shiffman D; Jones M; Green J
    BMC Bioinformatics; 2021 May; 22(1):229. PubMed ID: 33941085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
    Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
    Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
    Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
    Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
    Li Y; Chu F; Li P; Johnson N; Li T; Wang Y; An R; Wu D; Chen J; Su Z; Gu X; Ding X
    J Ethnopharmacol; 2021 May; 271():113854. PubMed ID: 33513419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Vimentin-Targeting Oral Compound with Host-Directed Antiviral and Anti-Inflammatory Actions Addresses Multiple Features of COVID-19 and Related Diseases.
    Li Z; Wu J; Zhou J; Yuan B; Chen J; Wu W; Mo L; Qu Z; Zhou F; Dong Y; Huang K; Liu Z; Wang T; Symmes D; Gu J; Sho E; Zhang J; Chen R; Xu Y
    mBio; 2021 Oct; 12(5):e0254221. PubMed ID: 34634931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFI44 is an immune evasion biomarker for SARS-CoV-2 and
    Zheng Q; Wang D; Lin R; Lv Q; Wang W
    Front Immunol; 2022; 13():1013322. PubMed ID: 36189314
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
    Fiscon G; Conte F; Farina L; Paci P
    PLoS Comput Biol; 2021 Feb; 17(2):e1008686. PubMed ID: 33544720
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.